07:06:19 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2023-11-09 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-05-04 Kvartalsrapport 2023-Q1
2023-02-23 Bokslutskommuniké 2022
2022-11-18 Extra Bolagsstämma 2022
2022-11-09 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-20 Ordinarie utdelning STENO 0.00 DKK
2022-05-19 Årsstämma 2022
2022-05-05 Kvartalsrapport 2022-Q1
2022-02-24 Bokslutskommuniké 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-21 Ordinarie utdelning STENO 0.00 DKK
2021-05-20 Årsstämma 2021
2021-05-06 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-15 Ordinarie utdelning STENO 0.00 DKK
2020-05-14 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-26 Bokslutskommuniké 2019
2019-11-06 Kvartalsrapport 2019-Q3
2019-08-20 Kvartalsrapport 2019-Q2
2019-05-07 Kvartalsrapport 2019-Q1
2019-02-21 Bokslutskommuniké 2018

Beskrivning

LandDanmark
ListaFirst North Denmark
SektorHälsovård
IndustriLäkemedel & Handel
Stenocare är verksamma inom hälsovårdsindustrin. Bolaget är specialiserade inom utveckling av medicinsk cannabis. Stenocare är en av de första aktören att ha påbörjat försäljning av medicinska cannabisoljor i Danmark. Bolaget kommer framöver även vända sig till övriga europeiska marknader med sitt produktutbud. Stenocares huvudkontor ligger i Randers.
2022-03-17 08:33:00

STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO

The Board of Directors and the Chief Executive Officer of STENOCARE A/S ("STENOCARE") hereby publishes the annual report of the fiscal year 2021. The annual report including the auditor's report is available as an attached file and on the websites of STENOCARE (https://stenocare.com/investor-relations/) and Nasdaq First North (http://www.nasdaqomxnordic.com/shares/microsite?Instrument=CSE196164).

Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments:

"Looking back at 2021, it was a year of hard work, with little to celebrate, financially. Nevertheless, significant value was created in 2021 that will prove important for 2022 and beyond

We continued selling our products in Sweden, completed the Danish facility upgrade and added more supply capacity. Towards the end of the year, the Danish legalization fell into place which provided assurance that medical cannabis is here to stay and our investments in the Danish facility are secured with the permanent legalization.

The tangible results of all our hard work in 2021 has already produced very significant news just after we concluded 2021. First, STENOCARE is now once again the only supplier of oil based medical cannabis products under the Pilot programme in Denmark. Second, we announced that the ongoing process of developing premium product is making real progress and third, we received approval to sell three new products in the UK market.

These milestones are not matched by others in Europe and point to a very interesting 2022 with an expected revenue run rate by the end of the year, that will enable an annual run rate of 15-20 million DKK (annualization of Q4 run rate)."